Examples of specific antigens of interest that highlight the capacity of IFNγ to augment the presentation of potential breast cancer-associated candidates include NY-BR-16, which increased from 11 peptides to 30 following IFNγ treatment, and breast cancer-associated antigen BRCAA1, which increased from three peptides to eight following IFNγ treatment. This evidence concerns the gene IFNG and breast carcinoma.